Transgelin 2 Participates in Lovastatin-Induced Anti-Angiogenic Effects in Endothelial Cells through a Phosphorylated Myosin Light Chain-Related Mechanism

Yuan Xiao, Yuhua Li, Jing Han, Yan Pan, Lu Tie, Xuejun Li*

State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences and Institute of System Biomedicine, Peking University, Beijing, China

Abstract

Background: Anti-angiogenic activity is considered to play a key role in the statin-induced anti-tumor effects. We aimed to identify new targets underlying this pleiotropic effect of lovastatin.

Methodology/Principal Findings: We investigated the inhibitory effects of lovastatin on endothelial cell biology and angiogenesis in vitro. Lovastatin at high doses inhibited endothelial cell migration and tube formation. Using two-dimensional gel electrophoresis followed by mass spectrometry, we identified the up-regulation of the actin-binding protein transgelin 2 in endothelial cells following treatment with lovastatin. Changes in transgelin 2 levels were confirmed by Western blot and confocal microscopy. We further demonstrated that the Rho signaling inactivation and actin depolymerization contributed to the up-regulation of transgelin 2. The knockdown of transgelin 2 by siRNA dramatically enhanced endothelial migration and tube formation, and meanwhile attenuated the inhibitory effects of lovastatin on cell motility. Moreover, theLovastatin-induced inhibition of myosin light chain phosphorylation was also reversed by transgelin 2 knockdown. The activation of Rho GTPase in the absence of transgelin 2 may represent a mechanism underlying the regulation of phosphorylated myosin light chain by transgelin 2.

Conclusions/Significance: These results strongly imply a novel role for transgelin 2 in the angiostatic activities of lovastatin.

Introduction

The expansion and propagation of malignant neoplasia are dependent on angiogenesis. Angiogenesis is controlled by a series of steps which involves endothelial proliferation, migration and differentiation. The network of mediators orchestrating this complex process would provide potential targets for pharmacological interventions in tumor therapy [1,2].

Statins are classical cholesterol lowering drugs. Recent studies have revealed that statins at high-doses possess protective pleiotropic effects against cancer. In addition to the direct effects in killing tumor cells, statins are also reported to inhibit the tumor-induced angiogenesis [3,4,5]. Those cholesterol-independent or ‘pleiotropic’ effects of statins are considered to be exerted through the inhibition of Rho family GTP-binding proteins. Given the great variety in the function and distribution of Rho family proteins, it would be important to identify new targets that mediate specific functions underlying those pleiotropic effects of statins.

Here we aimed at identifying new targets of lovastatin for its anti-angiogenic activities. Proteomic screening of endothelial cells was performed to identify differentially expressed proteins after lovastatin treatment. The functional significance of the potential targets and the regulatory mechanisms were also investigated. We showed that transgelin 2 was up-regulated by lovastatin, and unveiled a potential pathway for the lovastatin-induced anti-angiogenic activities.
10 μM, and capillary-like tubes have fragmented and crumbled into cell aggregates (Figure 1). Similarly, in transwell assays, endothelial cells treated with lovastatin at 1 and 10 μM were 48%-68% less motile than control, exhibiting significant motility inhibition.

The myosin-actin machinery powers cell motility. Phosphorylation of myosin light chain is needed for actin-myosin interaction. Figure 1C identified that lovastatin above 1 μM induced significant inhibition of phosphorylated myosin light chain (pMLC) in HUVECs. This is consistent with previous results that statins reduce cell motility partially by pMLC inhibition in a Rho kinase-dependent manner [2,8,10,11,12].

In clinical trials, the serum levels of lovastatin above micromolar are also readily achievable and generally well tolerated [13,14]. Therefore, we further investigated the anti-angiogenic effects of lovastatin at the dose of 10 μM, using proteomics approach to characterize novel target proteins.

Proteomics identification of transgelin 2 as a lovastatin-regulated downstream protein

HUVECs were treated with lovastatin (10 μM for 24 h) or vehicle (DMSO), followed by two-dimensional (2D)-gel separation of cell lysates. Figure 2A shows the representative 2D-gels, about 500 protein spots were detected consistently in each gel by Coomassie blue-staining and 302 spots were matched. Among the differentially expressed proteins, three major protein spots were selected and further analyzed by electrospray quadrupole/time-of-flight mass spectrometry (ES-Q-TOF-MS; Figure 2, B and C). Sequence analysis and database searching identified those proteins as glyceraldehyde-3-phosphate dehydrogenase (spot 1), transgelin 2 (spot 2), and B23 nucleophosmin (spot 3). The up-regulation of transgelin 2 was considered especially noteworthy because of its reported inhibitory role in the malignant phenotype of cancer cells [15,16], and was thus chosen for further study.

Immunoblotting identification of transgelin 2 up-regulation induced by lovastatin and through Rho GTPase inhibition and actin disruption

Transgelin 2 is a homologue of SM22/transgelin and member of a family of actin-binding proteins [17], while its function remains unknown. Confocal microscopic analysis revealed that transgelin 2 was present in the cytoplasm and co-localized with the F-actin cytoskeleton (Figure 3A), which may be indicative for a role in actin-based motility. To verify the up-regulation of transgelin 2 by lovastatin, immunoblotting was used to assess lovastatin’s effects. In the dose-dependent study, transgelin 2 expression showed about 37% increase (n = 3, p<0.05) over 10 μM lovastatin treatment (Figure 3C). Up-regulation of transgelin 2 expression was also time-dependent (Figure 3D). A significant transgelin 2 increase was observed at 24 h and persisted up to 48 h following lovastatin exposure (10 μM). Meanwhile, we also examined the effect of lovastatin on the cellular localization of transgelin 2 by confocal microscopy. Note the increase in transgelin 2 following 24 h ofLovastatin treatment (Figure 3E), which is consistent with the findings from Western blotting.

We next investigated the potential mechanism involved in the regulation of transgelin 2 by lovastatin. Previous studies have indicated the anti-angiogenic effects of statins are mediated by Rho GTPase suppression [7]. To test the effect of Rho kinase inhibition, we treated HUVECs with Y-27632, the Rho/ROCK pathway inhibitor. Y-27632 (20 μM, 24 h) mimicked the effect of lovastatin in up-regulating transgelin 2 expression (Figure 3E). Rho signaling blockade by lovastatin and Y-27632 could induce marked disruption of the actin cytoskeleton [18]. We directly treated HUVECs with cytochalasin B, a well-characterized disrupter of actin filaments. Cytochalasin B (5 μM, 24 h) extensively depolymerized actin filaments in HUVECs (data not shown), and up-regulation of transgelin 2 was detected by Western blot (Figure 3E). The results suggest that the induction of transgelin 2 by lovastatin is mediated through blockade of Rho activation and actin polymerization.

In this study, the dose-response pattern for transgelin 2 expression shifted toward the higher lovastatin concentrations when compared with transwell and tube formation assays (Figure 3 and Figure 1). This is probably due to the implementation of some anti-angiogenic mechanisms that are distinct from actin depolymerization [19–20]. We next addressed whether the transgelin 2 regulation does participate in physiological functions that are involved with lovastatin, or it is merely a phenomenon secondary to Rho inhibition. Therefore, we investigated the function of transgelin 2 by RNA interference (RNAi).

Transgelin 2 participates in angiogenesis and mediates lovastatin-induced migratory inhibition as well as pMLC suppression

The biological relevance of transgelin 2 in endothelial cells is poorly understood. We conducted transgelin 2 (TAGLN2) RNA interference, and the endothelial functions were analyzed. In the transwell cell migration model, transgelin 2 knock-down markedly increased HUVECs migration by 32% (Figure 4B). Similarly, endothelial tube formation was also increased by transgelin 2 RNAi by 16% (Figure 4C). When combining lovastatin treatment with RNAi transfection, the inhibitory effects of lovastatin in transwell assay was significantly alleviated by TAGLN2 RNAi (Figure 4B). The lovastatin-induced disruption of tube formation was not significantly reversed, apparently due to the overwhelming tube disruption by lovastatin (Figure 4C).

These results demonstrate the function of transgelin 2 underlying lovastatin’s effects in angiogenesis. However, no insight into the mechanisms by which transgelin 2 mediates angiogenesis is currently available.

Considering that pMLC is involved in statin-induced angiostatic effects [11], we examined whether it serves as an effector of transgelin 2. We measured the amount of pMLC in TAGLN2 siRNA transfected HUVECs. RNAi knockdown of transgelin 2 led to a 34% increase in the levels of pMLC. Moreover, transgelin 2 knockdown significantly reversed the pMLC inhibition by lovastatin (Figure 5A). The total amount of MLC (tMLC) was also increased following TAGLN2 RNAi.

MLC phosphorylation is under the regulation of Rho GTPase [21,22]. Indeed, we found significantly increased levels of active Rho GTPase in the absence of transgelin 2, and the lovastatin-induced inhibition was also partially reversed (Figure 5B). This finding was consistent with the changes in pMLC. These data further support the hypothesis that an important function of transgelin 2 is to suppress pMLC activity via Rho signaling, and therefore participating in the pMLC-mediated effects during lovastatin treatment.

Discussion

The mechanism by which high-dose statins inhibit angiogenesis remains to be fully characterized. In this study, we have demonstrated a role of transgelin 2 in lovastatin-induced anti-angiogenic effects on endothelial cells. To our knowledge, this study is the first to demonstrate a link between lovastatin and transgelin 2, especially for linking transgelin 2 to the lovastatin-inducing regulation induced by lovastatin and through Rho GTPase inhibition and actin disruption. Transgelin 2 participates in angiogenesis and mediates lovastatin-induced migratory inhibition as well as pMLC suppression. The biological relevance of transgelin 2 in endothelial cells is poorly understood. We conducted transgelin 2 (TAGLN2) RNA interference, and the endothelial functions were analyzed. In the transwell cell migration model, transgelin 2 knock-down markedly increased HUVECs migration by 32% (Figure 4B). Similarly, endothelial tube formation was also increased by transgelin 2 RNAi by 16% (Figure 4C). When combining lovastatin treatment with RNAi transfection, the inhibitory effects of lovastatin in transwell assay was significantly alleviated by TAGLN2 RNAi (Figure 4B). The lovastatin-induced disruption of tube formation was not significantly reversed, apparently due to the overwhelming tube disruption by lovastatin (Figure 4C).

These results demonstrate the function of transgelin 2 underlying lovastatin’s effects in angiogenesis. However, no insight into the mechanisms by which transgelin 2 mediates angiogenesis is currently available.

Considering that pMLC is involved in statin-induced angiostatic effects [11], we examined whether it serves as an effector of transgelin 2. We measured the amount of pMLC in TAGLN2 siRNA transfected HUVECs. RNAi knockdown of transgelin 2 led to a 34% increase in the levels of pMLC. Moreover, transgelin 2 knockdown significantly reversed the pMLC inhibition by lovastatin (Figure 5A). The total amount of MLC (tMLC) was also increased following TAGLN2 RNAi.

MLC phosphorylation is under the regulation of Rho GTPase [21,22]. Indeed, we found significantly increased levels of active Rho GTPase in the absence of transgelin 2, and the lovastatin-induced inhibition was also partially reversed (Figure 5B). This finding was consistent with the changes in pMLC. These data further support the hypothesis that an important function of transgelin 2 is to suppress pMLC activity via Rho signaling, and therefore participating in the pMLC-mediated effects during lovastatin treatment.

Discussion

The mechanism by which high-dose statins inhibit angiogenesis remains to be fully characterized. In this study, we have demonstrated a role of transgelin 2 in lovastatin-induced anti-angiogenic effects on endothelial cells. To our knowledge, this study is the first to demonstrate a link between lovastatin and transgelin 2, especially for linking transgelin 2 to the lovastatin-inhibiting regulation induced by lovastatin and through Rho GTPase inhibition and actin disruption. Transgelin 2 participates in angiogenesis and mediates lovastatin-induced migratory inhibition as well as pMLC suppression. The biological relevance of transgelin 2 in endothelial cells is poorly understood. We conducted transgelin 2 (TAGLN2) RNA interference, and the endothelial functions were analyzed. In the transwell cell migration model, transgelin 2 knock-down markedly increased HUVECs migration by 32% (Figure 4B). Similarly, endothelial tube formation was also increased by transgelin 2 RNAi by 16% (Figure 4C). When combining lovastatin treatment with RNAi transfection, the inhibitory effects of lovastatin in transwell assay was significantly alleviated by TAGLN2 RNAi (Figure 4B). The lovastatin-induced disruption of tube formation was not significantly reversed, apparently due to the overwhelming tube disruption by lovastatin (Figure 4C).

These results demonstrate the function of transgelin 2 underlying lovastatin’s effects in angiogenesis. However, no insight into the mechanisms by which transgelin 2 mediates angiogenesis is currently available.
induced pMLC inhibition. Furthermore, the identification of transgelin 2 in the regulation of angiogenesis may have important implications for vascular interventions, especially those for cancer treatment.

Transgelin 2 is an actin crosslinking/gelling protein [17,23,24]. Using 2D-DIGE proteomic profiling on HUVECs, we identified transgelin 2 as a candidate target of lovastatin. Although only little information about transgelin 2 is available, more is known about its closest homolog, the smooth muscle cell marker transgelin (SM22α), which plays important roles in several cellular events including cell migration and differentiation [23,25,26]. The human transgelin 2 protein shares 65% identity and 87% similarity with transgelin in aligned primary sequence space, and

![Figure 1. Lovastatin inhibits the angiogenesis and MLC phosphorylation of HUVECs in vitro. (A) HUVECs were pre-treated with various concentrations of lovastatin for 24 h. In vitro analysis of angiogenesis was carried out using capillary tube formation assay (upper panel; scale bar: 1 mm, ×4 objective) and transwell migration assay (lower panel; scale bar: 200 μm, ×20 objective). Note the dose-related decrease in the relative tube area and migrated cells. (B) Quantitative evaluation of the area covered by tubes (tube formation assay) and relative number of migrated cells (transwell assay) from (A). Data represent four independent experiments. (C) HUVECs were treated as in (A) and analyzed for phosphorylated and total MLC levels. β-actin was also probed as an internal control. Signal intensity of pMLC is expressed as percentage of control intensity ratio. n = 4. Data represent mean ± SEM. *, p<0.05, **, p<0.01, ***, p<0.001 compared with unstimulated control. doi:10.1371/journal.pone.0046510.g001]
Transgelin 2 has a much wider tissue distribution [17,27], yet little is known about its cellular functions.

The up-regulation of transgelin 2 was corroborated by Western blot. Meanwhile, studies have reported the down-regulation of transgelin 2 in highly-malignant tumor cells [15,16], and our study further expands the significance of transgelin 2 down-regulation to the scope of tumor angiogenesis. Further evidences are needed to consolidate the regulation of transgelin 2 in a tumorigenic context, as well as providing an in vivo evidence correlating transgelin 2 to the disruption of tumor angiogenesis, and the function of transgelin 2 in microvascular endothelial cells which comprise the tumor vasculature should also be clarified. The cross-system effects of transgelin 2 regulation are also an interesting issue, and comparative analysis between tumor cells versus endothelial cells [28] may provide insights involving the transgelin 2 function in tumor pathogenesis.

In this study, Y-27632 treatment achieved similar effects in transgelin 2 up-regulation asLovastatin. Besides, actin depolymerization by cytochalasin B also caused the transgelin 2 up-regulation. Collectively, these data may imply that Lovastatin regulates transgelin 2 expression by acting on cytoskeleton and via Rho inhibition. However, the mechanism underlying these effects leaves many questions open. Either the transcriptional suppression or post-transcriptional regulation is possibly involved, while further evidence is still needed.

Regarding the biological relevance of transgelin 2, endothelial cell motility and tube formation were evaluated in transgelin 2 knock-down cells. The significant increase of endothelial motility is consistent with the recently published findings in Hep3B cells [29], in which study the TAGLN2 knockdown rescued cell motility in PTK1-suppressed cells, and actin polymerization was supposed to be responsible for this effect. However, this observation was in
contrast to the study of Yoshino et al., who reported the transgelin 2 RNAi suppressed cell migration and invasion [30]. The current work does not provide a direct explanation for the discrepancy. However, according to unpublished observations, we tend to argue against our results for off-target effects. As regard to neoplastic tissues, the clinical significance of transgelin 2 expression is also controversial. For example, Mareike Elsner et al. and Zhang et al. have reported opposite results in the relevance of transgelin 2 in tumor malignancy or metastasis [31–32]. Therefore additional factors as the tissue- or cell- differences, as well as factors beyond protein expression, may also be concerned in the functional studies of transgelin 2.

The mechanism by which transgelin 2 mediates endothelial angiogenesis remains unclear. In our results, the RNAi study...
indicates a possible involvement of the phosphorylated MLC. MLC phosphorylation is important for actin-myosin interaction. Homologs of transgelin 2, the calponin family proteins, inhibit actin-myosin interaction without affecting the pMLC levels [33].

Our study provides evidence that transgelin 2, the calponin homolog protein, may directly regulate MLC phosphorylation and total expression. Most noteworthy is the hyper-activation of Rho GTPase by transgelin 2 ablation. Sequence analysis of transgelin 2 identified no recognizable Rho-related domains, therefore more insight should be provided into molecular mechanisms underlying the regulation of Rho activation. The overexpression experiments would also be important to consolidate the putative roles of transgelin 2 in angiogenesis.

Components of the statin-signaling pathways have provided potential targets to inhibit tumor angiogenesis and metastasis. For example, the inhibitors or RNA interference of Rho proteins are designed to improve anti-tumor therapy. However, the complexity of Rho signaling networks has presented challenges for target selection and treatment outcomes [34]. It should also be considered that putative interventions of transgelin 2 might be masked by its homologs. However, interestingly, transgelin 2 has been pointed out to constitute a complementary spatial distribu-
tion with its homolog, transgelin, the smooth muscle marker [27]. Zhang et al. have also reported the microvessel enrichment of transgelin 2 [32]. Therefore, the expression pattern of transgelin 2 may enlighten its potential for further exploitation.

In summary, this study presents transgelin 2 as a novel target in lovastatin-induced anti-angiogenic pathways. These findings may provide a new avenue for better understanding angiogenesis, and facilitate the development of potential angiostatic therapies especially for cancer.

Materials and Methods

Reagents and antibodies

M200 media was from Invitrogen (Carlsband, CA, USA). Lovastatin, Y-27632 and cytochalasin B were from Sigma-Aldrich Co. (St. Louis, MO, USA). Calcein AM and rhodamine conjugated phalloidin were from Biotium (Hayward, CA, USA). Antibodies for transgelin 2 (Proteintech Group, Inc., Chicago, IL, USA), MLCK (Abgent, Inc., San Diego, CA, USA), phospho-myosin light chain 2 and total myosin light chain 2 (Cell Signaling Technology Inc., Danvers, MA, USA) were also purchased from commercial sources.

Cell culture

Human umbilical vein endothelial cells (HUVECs) were purchased from Invitrogen and maintained in supplemented Medium 200 (Invitrogen/Gibco). All experiments were performed with cells between passages 2 to 5.

Two-dimensional gel electrophoresis and protein identification

Proteomic analysis was carried out as detailed previously [35]. Monolayer HUVECs were treated with or without 10 μM lovastatin for 24 h and lysed with solubilization buffer. Two-dimensional (2D) gel electrophoresis was performed using immobilized pH gradient strips (pH range: 3–10, Amersham Pharmacea Biotech, USA). Proteins were resolved by isoelectric focusing in the first dimension and SDS-PAGE in the second dimension, and visualized by Coomassie blue R-250 staining. Protein spots were then identified based on their discrete presence in the gel using the PDQuest software (Bio-Rad, Hercules, CA, USA).

Cell migration assay

Cell migration was assessed using transwell apparatus (8.0 μm pore size; Corning, New York, NY, USA). The lower compartment was filled with M200 medium containing 10% FBS. The upper compartment was filled with HUVECs re-suspended in M200 medium. After incubation at 37°C for 8 h, cells were fixed with 0.5% crystal violet in 20% ethanol. The migrated cells on the lower surface of the membrane were counted in 10 random fields using a light microscope (×20 objective).

Matrigel tube formation assay

HUVECs (1.6×10^4 cells per well) were seeded to the Matrigel (BD Biosciences, New Bedford, MA, USA) coated 96-well plates in Medium 200 (M200) complete growth medium supplemented with 5% FBS. In RNA interference experiments, 1% FBS was alternatively used to reveal more drastic effects of transfection. Cell culture was carried out at 37°C for 4 h. Tubes were stained with calcein AM and observed using an Olympus BX51
fluorescence microscope (Olympus, Tokyo, Japan) with digital camera (×4 objective). Fluorescence images were combined for extended depth of field and processed for analysis.

**Confocal microscopy**

Endothelial cells grown on cover slips were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS. After blocking with 5% BSA in PBS for 30 min, incubations with primary antibodies against transgelin 2 were performed overnight at 4°C and conjugated with appropriate DyLight 488-goat anti-rabbit IgG (H+L) secondary antibodies for 2 h at room temperature. To view fibrous actin, cells were stained by rhodamine-phalloidin for 2 h at room temperature. Confocal images were obtained with Leica TCS SP5 laser scanning confocal microscope equipped with a ×40 objective lens.

**Immunoblotting**

Cell lysates were collected in RIPA buffer and estimated with the BCA protein assay kit (Pierce, Rockford, IL, USA). Samples were subjected to 12% SDS-PAGE followed by transfer to PVDF membranes. Blotted membranes were incubated with primary antibodies in blocking buffer overnight at 4°C, followed by incubation with secondary antibodies for 1 h at room temperature. The blots were resolved using ECL chemiluminescence kit or alkaline phosphatase detection kit and quantified.

**References**

1. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273–296.
2. Zhou Q, Liao JK (2009) Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 15: 467–478.
3. Park HJ, Zhang Y, Georgescu SP, Johnson KL, Kong D, et al. (2006) Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Res 2: 93–102.
4. Li X, Liu L, Tupper JC, Banerjee DM, Winn RK, et al. (2002) Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 277: 15309–15316.
5. Kaneider NC, Reinisch CM, Dunzendorfer S, Meierhofer C, Djanani A, et al. (2001) Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by ceratinast. Atherosclerosis 158: 23–33.
6. Katsumoto M, Shingu T, Kawashima R, Nakata A, Nomura S, et al. (2005) Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 69: 1547–1555.
7. Vincent L, Albanese P, Bompais H, Uzan G, Vannier JP, et al. (2003) Insights in the molecular mechanisms of the anti-angiogenic effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Thromb Haemost 89: 530–537.
8. Laufs U, Kilter H, Konkol C, Wassmann S, Bolm M, et al. (2002) Impact of HMG CoA-reductase inhibition on small GTTPases in the heart. Cardiovasc Res 51: 912–920.
9. Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105: 739–745.
10. Kidera Y, Tsubaki M, Yamazoe Y, Shoji K, Nakamura H, et al. (2010) Biphasic effect of statins on integrin expression in human umbilical vein endothelial cells. Cell Biol Int 34: 75–84.
11. Zhang JCL, Helmkne B, Shum A, Du K, Yu WW, et al. (2002) SM22[beta] encodes a lineage-restricted cytoskeletal protein with a unique developmentally regulated pattern of expression. Mechanisms of Development 113: 161–166.
12. Kesh G, Ren C, Schmiedt G, Olenick C, Akories K (1997) Role of Rho protein in invasin-induced breakdown of actin cytoskeleton. J Pharmacol Exp Ther 283: 901–909.
13. Brandes RP (2005) Statin-mediated inhibition of Rho: only to get more NO? Circ Res 96: 927–929.
14. Vincent L, Chen W, Hong L, Misbahi F, Mishal Z, et al. (2001) Inhibition of endothelial cell migration by ceratinast, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 495: 159–166.
15. Amaro M, Ito M, Kimura K, Fukata Y, Chihara K, et al. (1996) Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271: 20246–20249.
16. Kamachandran C, Patil RV, Combrink K, Sharif NA, Seinivas SP (2011) Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells. Mol Vis 17: 1877–1890.
17. Shapland C, Hsuan JI, Totty NF, Lawson D (1993) Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J Cell Biol 121: 1065–1073.
18. Stanier P, Ahs-Hayesh S, Murdoch JN, Edlsteinn J, Coppel AJ (1998) Paragalogous smz2alpaha (Tagln) genes map to mouse chromosomes 1 and 9: further evidence for a paralogous relationship. Genomics 51: 144–147.
19. Dulkan JL, Giminia M, Scatena M, Sartore S, Small J (1998) Calpomin and SM 22 as differentiation markers of smooth muscle: spatiotemporal distribution during avian embryonic development. Differentiation 55: 1–11.
20. Lee EK, Han GY, Park HW, Song YJ, Kim CW (2010) Transgelin promotes migration and invasion of cancer stem cells. J Proteome Res 9: 5108–5117.
21. Rho JH, Roehrl MH, Wang JY (2009) Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J Proteome Res 8: 5610–5618.
22. Domanin S, Muschel S, Schwaiger C, Morath C, Winkler U, et al. (2008) Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther 7: 1658–1668.
23. Leung WK, Ching AK, Chan AW, Poon TC, Mian H, et al. (2011) A novel interplay between oncogenic PTK7 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene.
24. Yoshino H, Chiyomaru T, Enokida H, Kawaiaki K, Tatarazou S, et al. (2011) The tumour-suppressive function of CRL1 and its interaction with IRF1 and TSLC1 in epithelial inclusion cysts. Br J Cancer 104: 808–818.
25. Elmore M, Rauer S, Maier S, Schone C, Ballaf B, et al. (2012) MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100A10 as novel prognostic markers in Barrett’s dysplasia. Int J Mol Med 24: 789–794.
26. Zhang Y, Ye Y, Shen D, Jiang K, Zhang H, et al. (2010) Identification of transgelin-2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis. Cancer Sci 101: 523–529.

**RNA interference**

1.0 x 10^5 cells were resuspended with 2 μg of small interfering RNA (siRNA) targeting transgelin 2 (5’-GCAAAAGGCU-GAUCGGGUU-3’) or a scrambled negative control siRNA in 75 μL of electroporation buffer, followed by electroporation with the Gene Pulser Xcell system (Bio-Rad, Hercules, CA, USA).

**Rho GTase pull-down assay**

Rho activity was assayed by using a Rho activation kit (Thermo Fisher Scientific Inc., IL, USA) according to the manufacturer’s protocol. Briefly, cell lysate was incubated with GST-Rhotekin-RBD. Rho-GTP was then precipitated using agarose beads and blotted with anti-Rho-β antibodies.

**Statistical analysis**

Statistically evaluated data represent mean ± SEM of at least three independent experiments. The statistical significance of differences between groups was calculated by one-way analysis of variance, followed by Newman-Keuls multiple comparison tests to detect specific differences among multiple treatments. Differences of p<0.05 were considered significant.

**Author Contributions**

Conceived and designed the experiments: XL. Performed the experiments: YX YL. Analyzed the data: YX YL. Contributed reagents/materials/analysis tools: YX YL JH VP LT. Wrote the paper: YX XL.
33. Abe M, Takahashi K, Hiwada K (1990) Effect of calponin on actin-activated myosin ATPase activity. J Biochem 108: 835–838.

34. van der Meel R, Symons MH, Kudermatsch R, Kok RJ, Schifferers RM, et al. (2011) The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy. Drug Discov Today 16: 219–228.

35. Wu HL, Li YH, Lin YH, Wang R, Li YB, et al. (2009) Salvianolic acid B protects human endothelial cells from oxidative stress damage: a possible protective role of glucose-regulated protein 78 induction. Cardiovasc Res 81: 148–156.